HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February Drug-eluting stents Are they all equal?
|
|
- Ralf Norman
- 5 years ago
- Views:
Transcription
1 HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents Are they all equal? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic Hospital, Athens
2 HCS Working Group Seminars Macedonia Pallas Hotel, Friday 21 st February 2014 Drug-eluting stents How do I choose between them? Vassilis Spanos Interventional Cardiologist, As. Director 3 rd Cardiology Clinic Euroclinic Hospital, Athens
3 Mechanisms of in-stent restenosis In-stent restenosis is the result of: Inappropriate stent expansion or Neointimal hyperplasia or both V Spanos et al. The challenge of in-stent restenosis: insights from intravascular ultrasound review article (Eur Heart J Jan;24(2): )
4 Sirolimus-eluting stent: overcoming restenosis Sousa JE et al. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries : A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study ( Circulation. 2001;103: )
5 An unsuccessful trial - QuaDDS stent CONCLUSION: This single case report highlights the problem that late coronary thrombosis following paclitaxel eluting stent implantation may be an important limitation of restenosis prevention by some drug eluting stents. In the absence of other data, we think that combined antiplatelet treatment should be continued in the long term, unless it is contraindicated F. Liistro, A. Colombo: Late acute thrombosis after paclitaxel eluting stent implantation (Heart 2001;86: )
6 DES: a lot of different devices Efficacy Safety
7 DES: a lot of different devices Efficacy Late Lumen Loss Intimal Hyperplasia (IVUS) Restenosis Safety Complete endotthelization (OCT) Incomplete apposition (IVUS) Repeat Revascularization TVF (Death, CVA, MI) Stent thrombosis MI TVF (Death, CVA, TVR)
8 Late Lumen Loss with DES 0.31mm 0.09mm Ellis SG et al: Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: Analysis from the TAXUS-IV trial J Am Coll Cardiol. 2005;45(8):
9 Taxus vs. Cypher REALITY study MC. Morice et. al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial JAMA 2006: 295;
10 Taxus vs. Cypher: SIRTAX study CLINICAL FU only MACE at 9 months was 6.2% in the Cypher vs. 10.8% in the Taxus group (p=0.009) Difference driven by a lower rate of TLR (4.8% vs. 8.3%. p=0.03) Restenosis 6.6% vs. 11.7% (p=0.02) S. Windecker et.al. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization N Engl J Med 2005;353:
11 Taxus vs. Cypher stent: small vessels Lesions in vessels<2.8mm received either Taxus stents (n=180) or Cypher (n=180) Taxus stents did not reach the non- inferiority margin of 0.16mm late lumen loss Restenosis rate was 19.0% (Taxus) vs. 11.4% (Cypher, p=0.047) TLR was 14.7% vs. 6.6% respectively (p=0.008) J. Mehilli et.al. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels Eur Heart J 2006;27:
12 Taxus vs. Cypher: ISAR-DIABETES 250 pts with DM randomly assigned to receive Taxus or Cypher stents In-segment late luminal loss was 0.24mm greater in the Taxus stent group (p=0.002) In-segment restenosis rate was 16.5% for Taxus vs. 6.9% for Cypher group (p=0.03) TLR rate was 12.0% for Taxus vs. 6.4% for Cypher group (p=0.13). A. Dibra et.al. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients N Engl J Med 2005;353:
13 DES: a lot of different devices Efficacy Late Lumen Loss Intimal Hyperplasia (IVUS) Restenosis Safety Complete endotthelization (OCT) Incomplete apposition (IVUS) Repeat Revascularization TVF (Death, CVA, MI) Stent thrombosis MI TVF (Death, CVA, TVR)
14 Offsetting impact of ST and restenosis on the occurrence of death/mi G. Stone et.al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation Circulation 2007 Jun 5;115(22):2842-7
15 Late stent thrombosis E. McFadden et al. Late thrombosis in DES after discontinuation of antiplatelet therapy Lancet.2004; 364:
16 DES: a lot of different devices Efficacy Late Lumen Loss Intimal Hyperplasia (IVUS) Restenosis Safety Complete endotthelization (OCT) Incomplete apposition (IVUS) Repeat Revascularization TVF (Death, CVA, MI) Stent thrombosis MI TVF (Death, CVA, TVR)
17 Sirolimus-eluting stent: overcoming restenosis Sousa JE et al. Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries : A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study ( Circulation. 2001;103: )
18 Taxus vs. Cypher REALITY study More stent thromboses with Taxus (13, 1.9%) than Cypher (5, 0.7%), although the difference did not reach statistical significance MC. Morice et. al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial JAMA 2006: 295;
19 DES: a lot of different devices Efficacy Late Lumen Loss Intimal Hyperplasia (IVUS) Restenosis Safety Complete endotthelization (OCT) Incomplete apposition (IVUS) Repeat Revascularization TVF (Death, CVA, MI) Stent thrombosis MI TVF (Death, CVA, TVR)
20 Incomplete strut coverage in Late ST Ko et al Davlouros et al Miyazaki et al Guagliumi et al Alfonso et al n 18 DES 7 DES 6 DES 18 DES 8 BMS/ 7 DES DES type 14 SES/ 3 PES/ 1 EES Interval (months) Uncovered struts Patients with uncovered struts N/A 5SES/ 1PES 6 SES/ 10 PES/ 1 EES/ 1 ZES N/A 40±20 8 (3-62) 37±12 21 (6-60) 43±51-32% 29% 12.3% - 50% 100% 100% 83.3% 60% Ko et al, Int J Cardiovasc Img 2012, Davlouros et al, Circ J 2011, Miyazaki et al, Circ J 2012, Guagliumi et al, JACC Intv 2012, Anfonso et al, Heart 2012
21 DES coverage by OCT Papayannis AC et al, CCI 2012, Gutierrez-Chico JL et al, EHJ CI 2012
22 DES coverage by OCT: Discrepancy between differences in coverage and clinical outcome
23 DES: a lot of different devices Efficacy Late Lumen Loss Intimal Hyperplasia (IVUS) Restenosis Safety Complete endotthelization (OCT) Incomplete apposition (IVUS) Repeat Revascularization TVF (Death, CVA, MI) Stent thrombosis MI TVF (Death, CVA, TVR)
24 DES: a lot of different devices DES proven superior to BMS and used extensively in everyday practice in USA & Europe Cypher stent Taxus stent DES tested in clinical studies and/or used in everyday practice in Europe DES proven superior to BMS DES proven non-inferior to either Cypher or Taxus
25 The Endeavor stent: ENDEAVOR II Study TVF at 9 months was reduced from 15.1% to 7.9% with the Endeavor (p=0.0001) The rate of in-segment restenosis was reduced from 35.0% to 13.2% with Endeavor (p<0.0001) Fajadet J. et.al. Randomized, double-blind, blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial Circulation 2006; 114:
26 The Endeavor stent: ENDEAVOR III Study End points Endeavor (n=282) Cypher (n=94) In-stent mean lumen diameter (mm) <0.001 In-segment mean lumen diameter (mm) <0.001 In-stent diameter stenosis (%) <0.001 In-segment diameter stenosis (%) <0.001 In-stent binary restenosis (%) In-segment binary restenosis (%) In-stent late loss (mm) <0.001 In-segment late loss (mm) <0.001 Kandzari D. et.al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial JACC 2006; 46: p
27 Late Lumen Loss with DES 0.60mm 0.15mm Ellis SG et al: Relationship between angiographic late loss and target lesion revascularization after coronary stent implantation: Analysis from the TAXUS-IV trial J Am Coll Cardiol. 2005;45(8):
28 The Endeavor stent: SORT OUT III Study End points Endeavor (n=1162) Cypher (n=1170) p MACE (Cardiac death, MI, TVR) 113 (10.0%) 53 (5.0%) < TLR 71 (6.0%) 20 (2.0%) < All cause mortality 51 (4.0%) 32 (3.0%) Rasmunsen K. et.al. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial JACC 2006; 46:
29 Biolimus vs Sirolimus eluting stents 5 years follow up of the LEADERS Trial 857 pts with BES vs. 850 with SES P. Serruys, TCT 2012
30 Biolimus vs Sirolimus eluting stents 5 years follow up of the LEADERS Trial 857 pts with BES vs. 850 with SES P. Serruys, TCT 2012
31 Biolimus vs Sirolimus eluting stents 5 years follow up of the LEADERS Trial 857 pts with BES vs. 850 with SES P. Serruys, TCT 2012
32 DES: Different approaches
33 Αντίδραση υπερευαισθησίας J. Nebeker et al. (JACC. 2006;47: )
34 Paclitaxel vs. Everolimus eluting stents 2 years follow up of the SPIRIT IV Trial 2458 pts with EES vs with PES Stone G. et al 2 year follow up from the SPIRIT IV Trial J Am Coll Cardiol 2011:28;58(1):19-25
35 EES vs. SES: SORT OUT IV Trial 1390 pts (1805 lesions) with EES vs. 1384pts (1779 lesions) with SES Jensen L. et al Circulation.2012; 125:
36 Less ST with Everolimus eluting stents 4 years Registry, pts: 4212 lsns EES PES SES Lower risk of cardiac death/mi with EES compared with PES (hazard ratio:0.65; 95% confidence interval, ; 0.75; P<0.0001) Raber L. et al Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents Circulation.2012; 125:
37 ZES Resolute vs. EES 13 months follow up of the RESOLUTE All ComersTrial 1140 pts with ZES vs with EES 0.15mm 0.06mm Serruys P. et al Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents N Engl J Med 2010; 363:
38 New DES have to present convincing data S. Windecker et al. (PCR 2013)
39 The CoStar stent: PISCES Study Lowest in-stent late loss (0.38 mm, and 0.30 mm, p <0.01) and volume obstruction (8% and 5%, p <0.01) in the 30-day release groups (10µg, 30µg). 8.6% MACE for DES: death 0.5%, myocardial infarction 2.7%, and TLR 5.3%. P. Serruys et al. ( JACC 2005;46: )
40 CONCLUSIONS DES are complex devices with different characteristics and should be judged from their results as regards efficacy and safety There are second generation DES that have shown superiority compared to first generation (Cypher or Taxus) stents DES technology will continue to evolve aiming to devices with higher efficacy and safety
41 Thank you for your attention!
42 The Endeavor stent: More safe? 1 year follow up of the ZEST Trial 2645 pts randomized to ZES, SES, PES ZES SES PES Park D. et.al. Comparison of Zotarolimus-Eluting Stents With Sirolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization : The ZEST (Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent with Sirolimus-Eluting and PacliTaxel-Eluting Stent for Coronary Lesions) Randomized Trial JACC 2010; 56:
43 An unsuccessful trial: SCORE QuaDDS stent 7,4% restenosis rate (32,7%), but 10,3% stent thrombosis (0,7%) E. Grube et al. ( JACC 2004;44: )
44 Loss of side branches after Taxus stent implantation G. Stone, TCT 2005
45 2 years follow up of the COMPARE Trial 897pts (1286 lesions) with EES vs. 903pts (1294 lsns) with PES Smits P. et al 2 year follow up of a Randomized Controlled Trial of EES and PES for Coronary Revascularization in Daily Practice J Am Coll Cardiol. 2011;58(1):11-18
46 Paclitaxel vs. Everolimus eluting stents 2 years follow up of the SPIRIT III Trial 669 lesions with EES vs. 333 with PES 0.28mm 0.14mm Treatment with Everolimus stent resulted in a trend toward fewer re- interventions (TLR), fewer MIs and reduction in the composite of death/mi (4.8% vs. 8.1%, relative risk: 0.60, 95% CI: 0.36 to 0.99, p=0.055) Stone G. et al Randomized Comparison of Everolimus-Eluting Eluting and Paclitaxel-Eluting Stents.. Circulation. 2009;119:
47 Offsetting impact of ST and restenosis on the occurrence of death/mi G. Stone et.al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation Circulation 2007 Jun 5;115(22):2842-7
48 Offsetting impact of ST and restenosis on the occurrence of death/mi G. Stone et.al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation Circulation 2007 Jun 5;115(22):2842-7
49 Taxus vs. Cypher REALITY study MC. Morice et. al. Sirolimus- vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial JAMA 2006: 295;
50 DES: a lot of different devices Manufacturer Name Drug Stent material Polymer Status Abbott ZoMaxx Zotarolimus Tantalum/St steel Durable Sorin Janus Tacrolimus Stainless steel None CE Conor CoStar Paclitaxel Cobalt chromium Bioabsorbable CE Guidant Medtronic Xience V Endeavor Everolimus Cobalt chromium Durable CE Zotarolimus Cobalt chromium Durable CE Terumo Nobori Biolimus-A9 Stainless steel Bioabsorbable
51 The bioabsorbable stent: ABSORB Study 6-month follow-up 26 lesions In-stent diameter stenosis (%) 27 In-stent late loss (mm) 0.44 In-stent restenosis (%) 11.5 A stent made from a polylactic acid (PLA) backbone, with an everolimus/pla coating expected to dissolve completely after months Late loss and restenosis were greater than with current DES, probably due to the 15% shrinkage seen with the new stent Serruys P. American College of Cardiology 2007 Scientific Sessions; March 24, 2007.
52 DES: a lot of different devices DES proven superior to BMS and used extensively in everyday practice in USA & Europe Cypher stent Taxus stent DES tested in clinical studies and/or used in everyday practice in Europe DES proven superior to BMS DES proven non-inferior to either Cypher or Taxus
53 Taxus vs. Cypher stent: long lesions Lesions 24mm treated with long Cypher (223), Taxus (194), or BM stents Mean Lesion length treated with Cypher stent: 36.0 ± 14.9mm Mean Lesion length treated with Taxus stent: 36.3 ± 14.5mm 6 month in-segment restenosis rates were higher for Taxus (21.3%) than Cypher group (9.3%, p=0.002) 6 month MACE rate was similar: 13.0% for Cypher and 15.7% for Taxus stent Y. Kim et.al. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions Cath Cardiovasc Interv 2006;67(2):
54 The Xience V stent: SPIRIT III Study End point XIENCE V Taxus P In-segment late loss (mm) <0.001 (noninferiority) (superiority) In-stent late loss (mm) In-segment binary restenosis (%) Target vessel failure < (noninferiority) MACE (superiority) Stone G. American College of Cardiology 2007 Scientific Sessions. March 24, 2007
55 PES vs. SES: REALITY study MC. Morice. April tctmd.com
PCI for LMCA lesions A Review of latest guidelines and relevant evidence
HCS Working Group Seminars Met Hotel, Thursday 14 th February 2013 PCI for LMCA lesions A Review of latest guidelines and relevant evidence Vassilis Spanos Interventional Cardiologist, As. Director 3 rd
More informationDRUG ELUTING STENTS. Cypher Versus Taxus: Are There Differences? Introduction. Methods SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C.
DRUG ELUTING STENTS Cypher Versus Taxus: Are There Differences? SIGMUND SILBER, M.D., F.E.S.C., F.A.C.C. From the Cardiology Practice and Hospital, Munich, Germany Today, drug-eluting stents (DES) are
More informationFrom a DES to a BMS* Biosensors Clinical Trial Program. Taking the LEAD in DES Clinical Excellence. From Single de Novo.
Biosensors Clinical Trial Program Taking the LEAD in DES Clinical Excellence Our trials gather clinical data for this technology from a wide range of patients, including those with single de novo lesions,
More informationNobori Clinical Studies Up-dates. Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy
Nobori Clinical Studies Up-dates Gian Battista DANZI, M.D. Ospedale Maggiore Policlinico University of Milan, Italy Drug Eluting Stents High benefit in preventing restenosis and improving quality of life
More informationBIOFREEDOM: Polymer free Biolimus A9 eluting
TCTAP 2011 Seoul, April 27 29, 2011 BIOFREEDOM: Polymer free Biolimus A9 eluting Stents and Paclitaxel eluting stents Eberhard Grube MD, FACC, FSCAI Hospital Oswaldo Cruz - Dante Pazzanese, São Paulo,
More informationNew Generation Drug- Eluting Stent in Korea
New Generation Drug- Eluting Stent in Korea Young-Hak Kim, MD, PhD Department of Cardiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea Purpose To briefly introduce the
More information2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium. Seoul National University Hospital Cardiovascular Center
2010 Korean Society of Cardiology Spring Scientific Session Korea Japan Joint Symposium Does Lt Late Cth Catch up Exist Eiti in DES? : Quantitative Coronary Angiography Analysis Kyung Woo Park, MD Cardiovascular
More informationTaking DES technology from concept to long term clinical evidence. Aurore Bouvier Global Product Manager Biosensors Europe
Taking DES technology from concept to long term clinical evidence Aurore Bouvier Global Product Manager Biosensors Europe My conflicts of interest are: Full time employee of Biosensors Europe SA BA9 shows
More informationBiosensors Lunch Symposium
Are Current DES the Final Answer? BioFreedom TM : the Polymer-Free Biolimus A9TM Coated Stent Biosensors Lunch Symposium 25 th April 2013 Prof. Stephen WL Lee, JP 李偉聯 MD FRCP(Lon. Edin. Glas.) FHKCP FHKAM
More informationeluting Stents The SPIRIT Trials
Everolimus-eluting eluting Stents The SPIRIT Trials Gregg W. Stone, MD Columbia University Medical Center Cardiovascular Research Foundation Abbott XIENCE V Everolimus-eluting eluting Stent Everolimus
More informationDrug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis Alaide Chieffo
Drug Eluting Stents Sometimes Fail ESC Stockholm 29 Set 2010 Stent Thrombosis 11.45-12.07 Alaide Chieffo San Raffaele Scientific Institute, Milan, Italy Historical Perspective 25 20 15 10 5 0 Serruys 1991
More informationDrug eluting stents From revolution to evolution. Current limitations
Drug eluting stents From revolution to evolution Current limitations Eric Eeckhout Centre Hospitalier Universitaire Vaudois Lausanne - Switzerland eric.eeckhout@chuv.ch Overview Historical perspective
More informationTLR des Stents Actifs
TLR des Stents Actifs No Conflict of Interest Target Lesion Revascularization DES vs BMS Stettler C et al. Lancet 2007;370:937-48 N=18,023 58% 70% SES vs BMS: HR=0.30 (0.24-0.37), p
More informationKomplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents
Komplexe Koronarintervention heute: Von Syntax zu bioresorbierbaren Stents Prof. Dr. med. Julinda Mehilli Medizinische Klinik und Poliklinik I Klinikum der Universität München Campus Großhadern Key Factors
More informationDES in Diabetic Patients
DES in Diabetic Patients Charles Chan, M.D., FACC Gleneagles Hospital Singapore TCT ASIA PACIFIC 2007 Why do diabetics have worse outcome after PCI? More extensive atherosclerosis and diffuse disease Increase
More informationEberhard Grube MD FSCAI, FACC
SCAI 30 th Annual Scientific Sessions Orlando/Fla BMS and DES Thrombosis Differences among DES Eberhard Grube MD FSCAI, FACC HELIOS Heart Center Siegburg, Siegburg, Germany Stanford University, School
More informationPCI for Long Coronary Lesion
PCI for Long Coronary Lesion Shift of a General Idea with the Introduction of DES In the Bare Metal Stent Era Higher Restenosis Rate With Increasing Stent Length and Decreasing Stent Area Restenosis.6.4.2
More informationSafety of Drug-Eluting Stents in Acute Coronary Syndromes
Rotterdam, June 11 th 2012 Safety of Drug-Eluting Stents in Acute Coronary Syndromes Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationInnovation in Cardiovascular Interventions. New DES, Scaffolds and other Devices Have Angioplasty Results Improved
Innovation in Cardiovascular Interventions New DES, Scaffolds and other Devices Have Angioplasty Results Improved Alexandra Lansky, MD Yale University School of Medicine University College of London DES
More informationSecond Generation Drug Eluting Stents: From Inhibition to Healing
Second Generation Drug Eluting Stents: From Inhibition to Healing Mitchell W. Krucoff MD, FACC Professor of Medicine / Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke
More informationStephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank
From ABSORB Cohort A to ABSORB III and IV Randomized Trials Stephen G. Ellis, M.D. Professor of Medicine Director Invasive Services Co-Director Cardiac Gene Bank Disclosures Consultant, Abbott Vascular
More informationDrug eluting stents. Where are we now and what can we expect in 2003? Tony Gershlick Leicester
Drug eluting stents Where are we now and what can we expect in 2003? Tony Gershlick Leicester Trials Real World What we need i. Prevent restenosis cost effective Either : - Treat all at equivalent cost
More information3-Year Clinical Outcomes in the Randomized SORT OUT III Superiority Trial Comparing Zotarolimus- and Sirolimus-Eluting Coronary Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 5, NO. 8, 2012 2012 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2012.04.008
More informationStent Thrombosis: Patient, Procedural, and Stent Factors. Eugene Mc Fadden Cork, Ireland
Stent Thrombosis: Patient, Procedural, and Stent Factors Eugene Mc Fadden Cork, Ireland Definitions Early 1 yr TAXUS >6months CYPHER Incidence and Timing BMS Registry data
More informationDES In-stent Restenosis
DES In-stent Restenosis Roxana Mehran, MD Columbia University Medical Center The Cardiovascular Research Foundation DES Restenosis Mechanisms Predictors Morphological patterns Therapy approach Mechanisms
More informationPCI for In-Stent Restenosis. CardioVascular Research Foundation
PCI for In-Stent Restenosis ISR of BMS Patterns of In-Stent Restenosis Pattern I : Focal Type IA: Articulation / Gap Type IB: Marginal Type IC: Focal body Type ID: Multifocal Pattern II,III,IV : Diffuse
More informationCOMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands
COMPARE Trial Elvin Kedhi Maasstad Ziekenhuis Rotterdam The Netherlands TCTAP 2010 Seoul, Korea Disclosures Research Foundation of the Cardiology Department has received unrestricted research grants from:
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE GUIDANCE EXECUTIVE (GE) Review of TA152 drug-eluting stents for the treatment of coronary artery disease (part review of TA71) this guidance was originally
More informationCYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms. Campbell Rogers, M.D. Chief Technology Officer
Ground breaking, Life changing CYPHER (Polymer-based Sirolimus-eluting DES) New Stent Platforms Campbell Rogers, M.D. Chief Technology Officer Disclosure Statement of Financial Interest I am a full-time
More informationIn-stent Restenosis Diagnostic and Therapeutic Challenges. Kostis Raisakis General Hospital of Athens «G. Gennimatas»
In-stent Restenosis Diagnostic and Therapeutic Challenges Kostis Raisakis General Hospital of Athens «G. Gennimatas» Introduction With POBA, rates of acute and chronic vessel occlusion at 30% to 60%, secondary
More informationPolymer-Free Stent CX - ISAR
Polymer-Free Stent CX - ISAR Moo Hyun Kim, MD, FACC on behalf of Dr. Florian Krackhardt, Germany CX ISAR Stent : Features Intracoronary Stenting and Angiographic Results Strut Thickness of only 50/60 μm
More informationTailored bifurcation therapy
Tailored bifurcation therapy Dedicated self-expanding platform that conforms to the specific bifurcation anatomy Full bifurcation lesion coverage without creating a false carina Bifurcation DES technology
More informationBiolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program
TCT Asia 2006 Biolimus A9 Drug-Eluting Stents: Technical Aspects and a Comprehensive Review of the EU, Asia-Pacific, and US Clinical Trial Program Eberhard Grube MD FACC, FSCAI HELIS Heart Center Siegburg,
More informationPerspective of LM stenting with Current registry and Randomized Clinical Data
Asian Pacific TCT Perspective of LM stenting with Current registry and Randomized Clinical Data Patrick W. Serruys MD PhD Yoshinobu Onuma MD Seung-Jung Park MD, PhD 14:48-15:00, 2009 Symposium Arena, Level
More informationLate-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 4, NO. 5, 2011 2011 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.12.014 Late-Term Clinical
More informationNEW GENERATION DES WITH NEW GENERATION POLYMERS. Prof. Dr. Rainer Wessely, Duisburg, Germany
NEW GENERATION DES WITH NEW GENERATION POLYMERS Prof. Dr. Rainer Wessely, Duisburg, Germany Sousa J et al., JACC Cardioasv Interv 2010 10 years DES NEXT DES BMS + DAPT DES DES + DAPT S A F E T Y BMS E
More informationEXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017
EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts
More informationThe BIO revolution: bioadsorbable stents. Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino
The BIO revolution: bioadsorbable stents Federico Conrotto Cardiologia 2 Città della Salute e della Scienza di Torino BVS stent (Abbot Vascular) Strut Material: Poly-L-Lactic acid Coating Material: Poly-D,L-lactide
More informationCoronary Stent Choice in Patients With Diabetes Mellitus
Rome Cardiology Forum 2014 Coronary Stent Choice in Patients With Diabetes Mellitus Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University
More informationBiolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial
Limus Eluted From A Durable vs ERodable Stent Coating Biolimus-Eluting Stent With Biodegradable Polymer Versus Sirolimus-Eluting Stent With Durable Polymer: A Randomised, Non-Inferiority Trial Stephan
More informationBioabsorbable stents: early clinical results. Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals
Bioabsorbable stents: early clinical results Dr Angela Hoye MB ChB, PhD Senior Lecturer in Cardiology Hull & East Yorkshire Hospitals MY CONFLICTS OF INTEREST ARE: Clinical Events Committee member for
More informationLM stenting - Cypher
LM stenting - Cypher Left main stenting with BMS Since 1995 Issues in BMS era AMC Restenosis and TLR (%) 3 27 TLR P=.282 Restenosis P=.71 28 2 1 15 12 Ostium 5 4 Shaft Bifurcation Left main stenting with
More informationOCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis?
OCT in the Evaluation of Vascular Healing Following DES Implantation: Will It Be a Helpful Tool to Reduce Stent Thrombosis? Juan F. Granada, MD Medical Director, Skirball Center for Cardiovascular Research
More informationMoins de 6 mois d antiagrégants après DES?
Moins de 6 mois d antiagrégants après DES? High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France Pas de conflit d interet Was optimal duration of DAPT already established
More informationResolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program
Resolute in Bifurcation Lesions: Data from the RESOLUTE Clinical Program Prof. Ran Kornowski, MD, FESC, FACC Director - Division of Interventional Cardiology Rabin Medical Center and Tel Aviv University,
More informationOCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT
OCT Technology: Differences between Biodegradable and Durable Polymers: Insights from the LEADERS Trial LEADERS OCT Substudy Carlo Di Mario, MD Peter Barlis, MD Evelyn Regar, MD Peter Juni, MD Patrick
More informationWhat Stent to Use? JASVINDAR SINGH MD, FACC
What Stent to Use? JASVINDAR SINGH MD, FACC ASSOCIATE PROFESSOR OF MEDICINE WASHINGTON UNIVERSITY IN ST. LOUIS DIRECTOR, CARDIAC CATHETERIZATION LAB BARNES-JEWISH HOSPITAL What Stent to Use? Jasvindar
More informationDisclosure Eberhard Grube, M.D.
Disclosure Eberhard Grube, M.D. I disclose the following financial relationships: Consultant Sadra Medical, Core Valve, Biosensors, Orbus Neich, Cordis Johnson & Johnson, Boston Scientific, Mitralign,
More informationDrug eluting balloons in CAD
Drug eluting balloons in CAD Ioannis Iakovou, MD, PhD Interventional Cardiology 1 st Cath Lab Onassis Cardiac Surgery Center Drug-Eluting Balloons (DEB) Technology and Applications 1. Special Features
More informationUtilities and Pitfalls of Composite and Surrogate Endpoints in Clinical Trials. Cardiovascular Research Foundation Columbia University Medical Center
Utilities and Pitfalls of Composite and Surrogate Endpoints in Clinical Trials Helen Parise,, ScD Cardiovascular Research Foundation Columbia University Medical Center Common CV Clinical Endpoints Death
More informationStent Thrombosis in Bifurcation Stenting
Summit TCT Asia Pacific 2009 Stent Thrombosis in Bifurcation Stenting Associate Professor Tan Huay Cheem MBBS, M Med(Int Med), MRCP, FRCP(UK), FAMS, FACC, FSCAI Director, National University Heart Centre,
More informationIN-STENT RESTENOSIS. K.Boerlage-van Dijk CarVasZ 2014
IN-STENT RESTENOSIS K.Boerlage-van Dijk CarVasZ 2014 Definition ISR Angiographic: recurrent diameter stenosis >50% at the stent segment or edges (5-mm segments adjacent to stent) Mehran system morphological
More informationSCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents
SCAAR: Lower late and very late stent thrombosis rates with new generation drug eluting stents compared to bare metal stents Christoph Varenhorst, Giovanna Sarno, Göran Olivecrona, Per Tornvall, Johan
More informationDrug Eluting Stents: Bifurcation and Left Main Approach
TCT Asia 2006 Drug Eluting Stents: Bifurcation and Left Main Approach Eberhard Grube MD FACC, FSCAI Heart Center,, Germany Stanford University, School of Medicine, CA, USA DES in High Risk Lesions TAXUS
More informationJournal of the American College of Cardiology Vol. 47, No. 7, by the American College of Cardiology Foundation ISSN /06/$32.
Journal of the American College of Cardiology Vol. 47, No. 7, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.05.102
More informationConflict of interest :None. Meta-analysis. Zhangwei Chen, MD
Meta-analysis Addition of Cilostazol to Conventional Dual Antiplatelet Therapy Reduces the Risk of Cardiac Events and Restenosis after Drug-Eluting Stent Implantation Zhangwei Chen, MD Department of Cardiology,
More informationAngiographic long-term results after implantation of the paclitaxel-eluting coronary stent coroflex please : Data under real-world conditions
244 U. Gerk, B. Leithäuser, U. Schäfer, F. Jung, J.-W. Park Applied Cardiopulmonary Pathophysiology 14: 244-249, 2010 Angiographic long-term results after implantation of the paclitaxel-eluting coronary
More informationBioresorbable stents for all or for few? Franz-Josef Neumann
Bioresorbable stents for all or for few? Franz-Josef Neumann Personal: None Institutional: Conflict of Interest Speaker honoraria, consultancy fees and research grants from Lilly, Daiichi Sankyo, Sanofi-Aventis,
More informationPROMUS Element Experience In AMC
Promus Element Luncheon Symposium: PROMUS Element Experience In AMC Jung-Min Ahn, MD. University of Ulsan College of Medicine, Heart Institute, Asan Medical Center, Seoul, Korea PROMUS Element Clinical
More informationInterventional cardiology has made great strides in
STEPHEN G. ELLIS, MD Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic HARIS RIAZ, MD Resident, Department of Internal Medicine, Cleveland Clinic Bioresorbable stents:
More informationPaclitaxel-Eluting Coronary Stents in Patients With Diabetes Mellitus
Journal of the American College of Cardiology Vol. 51, No. 7, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.10.035
More informationBifurcation Stenting: IVUS and OCT Information
Bifurcation Stenting: IVUS and OCT Information Yoshinobu Murasato MD, PhD (New Yukuhashi Hospital) On behalf of J-REVERSE investigators October 14-15, 2011, Lisbon Proximal stent deformation induced by
More informationCurrent Status of BioresorbableScaffolds: Moving Forward or Backwards?
Evolving Science of Stents Current Status of BioresorbableScaffolds: Moving Forward or Backwards? Christian W. Hamm Kerckhoff Heart and Thorax Center Bad Nauheim and Medical Clinic I, University of Giessen,
More informationLong-term (2 5 years) adverse clinical outcomes associated with ZES versus SES, PES and EES: A Meta-Analysis
www.nature.com/scientificreports Received: 11 October 2016 Accepted: 16 June 2017 Published online: 25 July 2017 OPEN Long-term (2 5 years) adverse clinical outcomes associated with ZES versus SES, PES
More informationVascular Intervention // Coronary Drug-Eluting Stent System. Orsiro. Clinically proven. Highly deliverable. Ultrathin 60 μm struts
Vascular Intervention // Coronary Drug-Eluting Stent System Clinically proven Highly deliverable Ultrathin 60 μm struts The new benchmark for DES BIOFLOW-V 12-month clinical outcomes compared to Xience
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Byrne RA, Stone GW, Ormiston J, Kastrati A.
More informationComparison of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients With Native Coronary Artery Disease A Randomized Controlled Trial
Journal of the American College of Cardiology Vol. 48, No. 12, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2006.08.035
More informationA Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES.
A Polymer-Free Dual Drug-Eluting Stent in Patients with Coronary Artery Disease: Randomized Trial Versus Polymer-Based DES ISAR-TEST 2 Trial Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med.
More informationThe introduction of drug-eluting stents (DES) led
Stent Thrombosis With Drug-Eluting Versus Bare-Metal Stents Changing trends in the evolution of DES technology. By Usman S. Khokhar, MD, and Allen Jeremias, MD, MSc The introduction of drug-eluting stents
More information生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所
生物可吸收支架和聚合物涂层可降解 支架能消除支架内血栓吗? 钱菊英,MD, FACC,FESC 复旦大学附属中山医院上海市心血管病研究所 PCI milestones Pre Post Biodegradable polymer? 1 st revolution 1977 PTCA 2 nd revolution 1988 BMS 3 rd revolution 2000 DES Bioresorbable
More informationImportant LM bifurcation studies update
8 th European Bifurcation Club 12-13 October 2012 - Barcelona Important LM bifurcation studies update I Sheiban E-mail: isheiban@yahoo.com Unprotected LM Percutaneous Revascularization What is important
More informationANGIOPLASY SUMMIT 2007 TCT ASIA PACIFIC. Seoul, Korea: April The problem is exaggerated: Data from Real World Registries
ANGIOPLASY SUMMIT 007 TCT ASIA PACIFIC Seoul, Korea: 5-7 7 April 007 15 min Plenary Session: State-of of-the-art Lectures The problem is exaggerated: Data from Real World Registries Antonio Colombo Centro
More informationBIOFLOW by Orsiro stents
BIOFLOW by stents Byeong-Keuk Kim, MD, PhD Division of Cardiology, Department of Internal Medicine, Severance Cardiovascular Hospital, Yonsei University College of Medicine Key Benefits Clinically proven
More informationComparison of Everolimus-Eluting and Paclitaxel- Eluting Coronary Stents in Patients Undergoing Multilesion and Multivessel Intervention
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 3, NO. 12, 2010 2010 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. DOI: 10.1016/j.jcin.2010.09.014 Comparison
More informationPCI with Polymer-free Stent
PCI with Polymer-free Stent Florian Krackhardt, M.D. Department of Cardiology Charité Campus Virchow-Klinikum University Hospital Berlin, Germany Drug Eluting Stents: Present Coating Technology Solution
More informationCatch-up Phenomenon: Insights from Pathology
Catch-up Phenomenon: Insights from Pathology Michael Joner, MD CVPath Institute Inc. Gaithersburg, MD USA Path Lessons learned from the BMS and DES (1 st Gen) era Neointimal Thickness [mm] In Stent Re
More informationContemporary therapy of bifurcation lesions
Contemporary therapy of bifurcation lesions Dr Angela Hoye MB ChB PhD MRCP Interventional Cardiologist Kingston-upon-Hull, UK Hull The challenge of bifurcations Risk of peri-procedural infarction Relatively
More informationTNT Session. The latest clinical evidence in diabetics for the Amphilimus TM eluting polymer-free DES. Rafael Romaguera, MD
TNT Session The latest clinical evidence in diabetics for the Amphilimus TM eluting polymer-free DES Rafael Romaguera, MD Hospital de Bellvitge Barcelona Spain Disclosure Statement of Financial Interest
More informationmalapposition assessed by OCT
Stent t coverage and malapposition assessed by OCT Myeong-Ki Hong, M.D. Ph D Professor of Medicine Division of Cardiology, Severance Cardiovascular Hospital Yonsei University College of Medicine, Seoul,
More informationBioresorbable polymer drug-eluting stents in PCI
EARN 3 FREE CPD POINTS CARDIOVASCULAR Leader in digital CPD for Southern African healthcare professionals The BIOFLOW-V trial, using the Orsiro ultrathin strut stent with biodegradable polymer, showed
More informationSKG Congress, 2015 EVOLVE II. Stephan Windecker
SKG Congress, 2015 EVOLVE II Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland BIODEGRADABLE POLYMER DES Stefanini,
More informationPCI for Left Main Coronary Artery Stenosis. Jean Fajadet Clinique Pasteur, Toulouse, France
PCI for Left Main Coronary Artery Stenosis Jean Fajadet Clinique Pasteur, Toulouse, France Athens, October 19, 2018 Left Main Coronary Artery Disease Significant unprotected left main coronary artery disease
More informationZotarolimus- and Paclitaxel-Eluting Stents in an All-Comer Population in China
JACC: CARDIOVASCULAR INTERVENTIONS VOL. 6, NO. 7, 2013 2013 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION ISSN 1936-8798/$36.00 PUBLISHED BY ELSEVIER INC. http://dx.doi.org/10.1016/j.jcin.2013.03.001
More informationDEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea.
DEB experience in Gachon Universtiy Gil Hospital (in ISR) Soon Yong Suh MD., PhD. Heart Center Gachon University Gil Hospital Seoul, Korea. In-stent restenosis (ISR) Remains important issue even in the
More information2-Year Follow-Up of a Randomized Controlled Trial of Everolimus- and Paclitaxel-Eluting Stents for Coronary Revascularization in Daily Practice
Journal of the American College of Cardiology Vol. 58, No. 1, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.023
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationTechnical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD
Technical considerations in the Treatment of Left Main Lesions Ioannis Iakovou, MD, PhD Onassis Cardiac Surgery Center, Athens, Greece Critical issues in LM PCI Anatomic variability Techniques Variability
More informationDUREE de la BITHERAPIE dans les ETUDES LEADERS. J BERLAND Clinique Saint Hilaire ROUEN
DUREE de la BITHERAPIE dans les ETUDES LEADERS J BERLAND Clinique Saint Hilaire ROUEN LEADERS all-comers Trial Design Stable and ACS Patients Undergoing PCI Assessor-blind 1:1 Randomisation N=1700 Patients
More informationFor Personal Use. Copyright HMP 2014
Original Contribution Long-Term Safety and Efficacy of the Everolimus-Eluting Stent Compared to First-Generation Drug-Eluting Stents in Contemporary Clinical Practice Israel M. Barbash, MD, Sa ar Minha,
More informationINTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY. SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS
INTERVENTIONAL VASCULAR DIAGNOSTICS AND THERAPY SeQuent Please NEO CLINICAL EVIDENCE AND COST / BENEFIT EFFECTIVENESS Table of Contents Overview SeQuent Please - DCB Scientific Publications SeQuent Please
More informationAre New DES Designs Safer?
cit0711_f6_krucoff.qxd 8/24/11 2:03 PM Page 56 Are New DES Designs Safer? Changes in stent platform, polymer, and drug components have led to improved outcomes. BY ASHWANI SASTRY, MD, AND MITCHELL W. KRUCOFF,
More informationBiodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial
Clinical trial report Biodegradable polymer limus-eluting stents are noninferior to permanent polymer-based stents: the ISAR-TEST-4 trial Biodegradable polymer drug-eluting stent (DES) platforms have the
More information2-Year Patient-Related Versus Stent-Related Outcomes
Journal of the American College of Cardiology Vol. 60, No. 13, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.004
More informationDrug Eluting Stents overhyped, overused and overpriced?
Advanced Angioplasty 2008 BCIS 23 rd Jan 2008 Drug Eluting Stents overhyped, overused and overpriced? William Wijns MD, PhD Cardiovascular Center Aalst http://www.cardio-aalst.be William.Wijns@village.uunet.be
More informationCoronary Stents: Past, Present and Future
Kardiologie Kardio Lunch 07.04.2016 Coronary Stents: Past, Present and Future Christoph Kaiser Universitätsspital Basel Rubin GS, The first balloon-expandable coronary stent, University of Queensland Press
More informationYukon Chrome PC. Translumina trust is what counts. Sirolimus Eluting CoCr Coronary Stent System. 5-Years Randomized Clinical Follow-Up
Sirolimus Eluting CoCr Coronary Stent System Yukon Chrome PC 5-Years Randomized Clinical Follow-Up Translumina trust is what counts trust is what counts Yukon Chrome PC DES coating with excellent long-term
More informationEvaluation of a novel stent technology: the Genous EPC capturing stent Klomp, M.
UvA-DARE (Digital Academic Repository) Evaluation of a novel stent technology: the Genous EPC capturing stent Klomp, M. Link to publication Citation for published version (APA): Klomp, M. (2012). Evaluation
More informationNon-LM bifurcation studies of importance in 2011
7th European Bifurcation Club 14-15 October 2011 LISBON Goran Stankovic MD, PhD Non-LM bifurcation studies of importance in 2011 October 15 th : 08:00 08:10 DKCRUSH-II: A Prospective Randomized Trial of
More informationLong-Term Comparison of Everolimus-Eluting and Sirolimus-Eluting Stents for Coronary Revascularization
Journal of the American College of Cardiology Vol. 57, No. 21, 2011 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2011.01.023
More information